Invesco Ltd. Acquires 438,635 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Invesco Ltd. lifted its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 545.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 519,010 shares of the company's stock after acquiring an additional 438,635 shares during the period. Invesco Ltd. owned approximately 0.99% of Kodiak Sciences worth $5,164,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of KOD. PNC Financial Services Group Inc. raised its holdings in Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after buying an additional 2,988 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Kodiak Sciences by 6.2% in the fourth quarter. American Century Companies Inc. now owns 59,967 shares of the company's stock worth $597,000 after purchasing an additional 3,515 shares during the last quarter. US Bancorp DE purchased a new position in Kodiak Sciences during the 4th quarter worth $40,000. Bank of New York Mellon Corp grew its holdings in shares of Kodiak Sciences by 5.3% in the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock valued at $976,000 after acquiring an additional 4,927 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Kodiak Sciences by 61.4% during the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company's stock worth $206,000 after purchasing an additional 7,871 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $3.00 price objective on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Stock Down 1.1 %

Shares of NASDAQ KOD traded down $0.05 during mid-day trading on Thursday, reaching $4.31. 52,255 shares of the company were exchanged, compared to its average volume of 341,871. The stock has a market capitalization of $227.41 million, a PE ratio of -1.17 and a beta of 2.40. Kodiak Sciences Inc. has a 52 week low of $1.92 and a 52 week high of $11.60. The company's 50 day moving average price is $3.24 and its 200 day moving average price is $5.43.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.06. On average, sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.